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Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely 
paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes 
prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic 
inﬂ  ammation as the common denominators in the evolution of insulin resistance and diabetes. Of 
all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, 
in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating 
oxidative stress and inﬂ  ammation; rendering them attractive tools for prevention of insulin resis-
tance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone 
and metformin have been shown to exert anti-oxidative and anti-inﬂ  ammatory effects in vascular 
beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of 
morbidity and mortality in the affected population. The combination of pioglitazone and metformin 
would thus appear to be an effective pharmacological intervention in prevention and treatment of 
diabetes. Finally, this review will address the currently available evidence on diabetic cardiomy-
opathy and the potential role of combination therapy with pioglitazone and metformin.
Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, 
atherosclerosis, diabetic cardiomyopathy
Introduction
The recent escalation of obesity from an individual health problem to a major public health 
issue reaching epidemic proportions has drawn attention to a constellation of abnormalities 
(abdominal obesity, hypertension, dyslipidemia) collectively referred to as metabolic syn-
drome. As an indicator of insulin resistance and a harbinger of diabetes, this syndrome has 
been associated with major cardiovascular mortality and morbidity (Galassi et al 2006). The 
surge in the prevalence of diabetes to epidemic proportions around the world has followed 
the same trends as the obesity and metabolic syndrome. The current global prevalence of 
type 2 DM is approximately 150 million with a predicted increase to 215 million by 2010 
and 300 million by 2025 reported by CDC (2006). Therefore, it would seem intuitive to 
blame excess body weight and excess adipose tissue mass for causing insulin resistance and 
diabetes. Yet, the exact pathophysiological events leading to the development of diabetes 
or cardiovascular disease in metabolic syndrome remain unknown. This review aims to go 
over the current literature on the pathogenesis of diabetes and effects of two different insulin 
sensitizers, on the treatment of diabetes and cardiovascular complications of diabetes.
Pathogenesis of insulin resistance and diabetes
Subjects with type 2 diabetes (T2DM) are characterized by chronic insulin resistance 
with poor β-cell compensation. Although there is much descriptive information on the 
pathogenesis of type 2 diabetes (T2DM), the underlying mechanisms remain unknown. 
The initial pathophysiologic event is usually insulin resistance associated with obesity Vascular Health and Risk Management 2007:3(6) 968
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and a sedentary lifestyle. Along with the development of 
insulin resistance, insulin secretory decompensation devel-
ops, leading to impaired glucose tolerance, and eventually 
T2DM (Martin et al 1992). It is not well understood why 
obesity causes insulin resistance. However, the hypotheses 
linking obesity to insulin resistance generally fall into the 
following categories: inﬂ  ammation, lipotoxicity, oxidative 
stress and endoplasmic reticulum stress.
Obesity is associated with increased accumulation of 
macrophages in adipose tissues and increased levels of pro-
inﬂ  ammatory cytokines (Di Gregorio et al 2005). In addition, 
obesity results in excess lipid accumulation not only in adipose 
tissue but also in tissues such as the liver, skeletal muscle, 
heart and pancreas (Unger 2003). There is a strong correla-
tion between intramyocellular fat content (IMCL) and insulin 
resistance (Perseghin et al 1999; Friedman 2002). Ectopic 
lipid accumulation with resultant functional impairment has 
been called lipotoxicity, a pathophysiologic event preceding 
diabetes (Friedman 2002). Increased level of reactive oxy-
gen species (ROS) has been also known as a culprit in the 
pathogenesis of insulin resistance and diabetic complications 
(Petersen et al 2004; Schrauwen and Hesselink 2004; Houstis 
et al 2006; Mehta et al 2006). Insulin resistance and diabetes 
are associated with disruption and uncoupling of several key 
oxidative reactions that result in excessive production of ROS 
at mitochondrial and cellular levels (Nishikawa et al 2000). 
Increased production of reactive oxygen species in mito-
chondria, accumulation of mitochondrial DNA damage, and
progressive respiratory chain dysfunction are associated with 
atherosclerosis or cardiomyopathy in human investigations 
and animal models of oxidative stress (Mehta et al 2006; 
Madamanchi and Runge 2007). More recently, obesity-
induced endoplasmic reticulum stress (increased unfolded 
protein response due to the disruption of the smooth operation 
of endoplasmic reticulum) has been demonstrated to result in
peripheral insulin resistance (Hotamisligil 2005). Lipotoxicity, 
oxidative stress and endoplasmic reticulum stress are associ-
ated with activation of nuclear factor-κB (NF-κB), chronic 
inﬂ  ammation and insulin resistance (Figure 1). Interventions 
aimed at modulating any of the above mentioned pathways are 
potential therapies for diabetes and its complications.
Pharmaceutical intervention
to relieve insulin resistance
(insulin sensitizers)
Because insulin resistance is the key feature of type 2 
diabetes, much drug development has been focused on insulin 
sensitizers. At present, two classes of drugs are used as insulin 
sensitizers: biguanides (metformin), and thiazolidinediones 
(rosiglitazone and pioglitazone). The mechanism of action 
of these drugs is not well understood. Metformin is relatively 
more active in the suppression of hepatic glucose production 
(DeFronzo et al 1991; Stumvoll et al 1995), and thiazolidin-
ediones are more active in stimulation of muscle glucose 
uptake (Nolan et al 1994; Yki-Jarvinen 2004).
Metformin
Metformin is the only biguanide available in the U.S. and 
it is one of the most commonly used anti-diabetic medica-
tions. Several studies have demonstrated improved periph-
eral insulin sensitivity following metformin treatment in 
diabetic patients (Widen et al 1992; Velazquez et al 1994; 
Dorella et al 1996; Li et al 1999; Moghetti et al 2000). In 
one study, metformin produced an improvement in basal, 
but not insulin stimulated, glucose transport, and no effect 
on insulin secretion (Morel et al 1999) yet in another study, 
metformin did not have any effect on peripheral insulin 
sensitivity (Rasouli et al 2005). The improvement in insulin 
sensitivity by metformin was less than that observed with 
thiazolidinedione in a recent study in diabetic patients 
receiving a sulfonylurea (Kim et al 2002; Rasouli et al 
2005). Hence, the data suggest that metformin has a primary 
action on hepatic glucose production, either through direct 
activation of insulin receptor (Gunton et al 2003) or inhibi-
tion of key enzymes in the gluconeogentic pathways (Cusi 
et al 1996; Dorella et al 1996). Recent studies have shown 
that metformin stimulated AMP kinase activity (Zhou et al 
2001), and enhanced the peroxisome proliferator-activated 
receptor-gamma coactivator-1alpha (PGC-1α) expression 
(Suwa et al 2006). Both AMP kinase and PGC are major 
regulators of fatty acid oxidation; hence, metfomin might 
improve lipotoxicity. Indeed metformin decreased muscle 
fat content in diabetic subjects (Mathieu-Costello et al 2003), 
however, we did not detect any change in IMCL in our study, 
with metformin (Rasouli et al 2005). Metformin has also 
favorable effects on some inﬂ  ammatory markers such as CRP 
levels. However, the effect of thiazolidinedione or weight 
loss on lowering CRP was more pronounced (Chu et al 2002; 
The Diabetes Prevention Program Research Group 2005). 
We have previously reported no change in plasma levels of 
TNFα or adiponectin in subject with impaired glucose toler-
ance after treatment with metformin for 10 weeks, however, 
resistin level decreased signiﬁ  cantly in that study (Rasouli 
et al 2006). In addition, metformin did not change the number 
of adipose tissue macrophages as markers of inﬂ  ammation 
(Bodles et al 2006; Di Gregorio et al 2005).Vascular Health and Risk Management 2007:3(6) 969
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The impact of metformin on oxidative stress has also 
been investigated in several studies. It has been shown that 
metformin can quench the surge in reactive oxidant species 
in insulin resistance and diabetes. In a study by Rosen et al 
on Goto-Kakizaki (GK) rat model of type 2 diabetes, Metfor-
min was noted to ameliorate mitochondrial oxidative stress 
as demonstrated by a reduction in mitochondrial aconitase 
activity. In addition, metformin prevented the rise in oxi-
dized proteins (carbonyl moieties) and lipid peroxides that 
are usually observed in this model of type 2 diabetes (Rosen 
and Wiernsperger 2006). Furthermore, metformin has been 
shown to reduce ROS levels in human leukocytes by either 
directly scavenging the free radicals or modulating their 
intracellular production (Bonnefont-Rousselot et al 2003).
Thiazolidinediones
The thiazolidinedione derivatives, pioglitazone and rosiglitazone, 
are synthetic ligands for peroxisome proliferative-activated 
receptorγ (PPARγ) which improve insulin sensitivity. 
PPARγ is mainly expressed in adipose tissue; however, 
improved insulin sensitivity is a function that primarily 
involves glucose transport into skeletal muscle. This effect is 
poorly understood, but it is thought to be due to redistribution 
of lipid from ectopic sites to subcutaneous adipose tissue. 
PPARγ agonists promote adipocyte differentiation, and they 
promote FFA uptake and storage in subcutaneous adipose 
rather than visceral adipose tissue or ectopic sites (muscle or 
liver) (Bajaj et al 2003; Rasouli et al 2005). In addition to the 
favorable effect on lipotoxicity, we have previously reported 
that thiazolidinediones decreased inﬂ  ammatory responses in 
insulin resistance (Di Gregorio et al 2005; Bodles et al 2006) 
by reducing the number of adipose tissue macrophage. Pio-
glitazone promotes apoptosis in adipose tissue macrophages 
along with improvement in insulin sensitivity (Bodles et al 
2006). PPAR ligands have been shown to regulate inﬂ  am-
matory cytokines like TNFα, CRP, PAI and adiponectin 
as well (Chu et al 2002; Yki-Jarvinen 2004; Rasouli et al 
2005, 2006). Thiazolidinediones have also been shown to 
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Figure 1 Diabetes is characterized by decompensated insulin secretion for insulin resistance at target organs including adipose tissue, liver and muscle. Insulin resistance 
is associated with increased proinﬂ  ammatory cytokines. Inﬂ  ammatory pathways in insulin resistance can be initiated by extracellular mediators such as cytokines and free 
fatty acid (FFA) or by intracellular stresses such as ER stress, excess ROS production by mitochondria or lipotoxicity.   Activation of NF-κB pathway leads to induction of 
chemokines that recruit inﬂ  ammatory cells, such as macrophages. (FFA Free fatty acid, ER Endoplasmic reticulum, DAG diacylglycerol, LCFA long chain fatty acid, IR insulin 
receptor).Vascular Health and Risk Management 2007:3(6) 970
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exert potent antioxidant effects. In a study by Hwang and 
colleagues, rosiglitazone reduced NADPH oxidase activity 
and superoxide ion O2− generation in the vascular tissues 
obtained from obese, diabetic, leptin receptor-deﬁ  cient 
(db(−)/db(−)) mice (Hwang et al 2007). Similarly, piogli-
tazone has been found to reduce superoxide ion O2− gen-
eration in human coronary artery endothelial cells (Mehta 
et al 2003).
Cardiovascular complications
of diabetes
Cardiovascular disease is the major cause of mortality and 
morbidity in diabetes and is usually due to atherosclerosis 
in the coronary, cerebral and other peripheral vascular beds 
(Tziakas et al 2005; Pambianco et al 2006). Yet, myocardial 
dysfunction in the absence of epicardial coronary atheroscle-
rosis has also been described and accounts for some cases of 
congestive heart failure in diabetics (Rubler et al 1972).
Accelerated atherosclerosis
in diabetes
Several lines of evidence point to endothelial dysfunction and 
loss of endothelial vasoreactivity as one of the initial events in 
atherosclerotic plaque formation (Davignon and Ganz 2004). 
The dysfunctional endothelium subsequently expresses a host 
of cell surface receptors including intercellular adhesion mole-
cule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-1) 
as well as receptors for oxidized lipid particles such as leptin-
like oxLDL receptor (LOX-1) which facilitate inﬂ  ammatory 
cell recruitment and oxidized LDL transport to the intimal 
layer. The ingestion of oxidized lipid particles by these cells 
results in further activation of inﬂ  ammatory cells and release 
of cytokines and growth factors which perpetuate the vicious 
cycle of inﬂ  ammation, cell recruitment, lipid particle ingestion 
and growth; ultimately leading to an atherosclerotic plaque. 
The acceleration of this process in diabetes could be attributed 
to several potential mechanisms. There is growing evidence 
that excessive ROS formation in diabetes leads to endothelial 
dysfunction (Vincent and Taylor 2006). The ﬁ  rst evidence of 
endothelial dysfunction in human type 1 and type 2 diabetes 
were reported from examination of penile corpura cavernosa 
(Saenz de Tejada et al 1989). Subsequent studies conﬁ  rmed loss 
of endothelial vasoreactivity in other vascular beds including 
coronary arteries (Nitenberg et al 1993). Although the exact 
mechanism of endothelial dysfunction in diabetics has not 
been elucidated, several studies point to reduced NO bioavail-
ability and that tight glycemic control can improve endothelial 
reactivity (Rodriguez-Manas et al 2003). Our laboratory data 
indicates that increased ROS induces LOX-1 expression which 
not only facilitates ox-LDL incorporation into endothelium but 
also enhances expression of adhesion molecules ICAM-1 and 
VCAM (Li and Mehta 2000; Chen et al 2001; Li et al 2003). 
The dyslipidemic milieu of diabetes ensures a continued 
ﬂ  ux, oxidation and uptake of LDL particles into the eventual 
atherosclerotic plaque.
Effects of thiazolidinediones 
and metformin in decelerating 
atherosclerotic plaque formation
in diabetes
Thiazolidiones and in particular pioglitazone have been shown 
to improve endothelial function in diabetes. In a randomized 
controlled trial, Martens and colleagues demonstrated that 
four weeks of therapy with pioglitazone improves shear stress-
induced ﬂ  ow mediated vasodilation (an endothelial dependent 
phenomenon) of brachial artery in patients with type 2 diabe-
tes with no effect on endothelium independent vasodilation 
(Martens et al 2005). In addition, pioglitazone has also been 
shown to reduce LOX-1 as well as VCAM expression which 
can potentially prevent plaque formation (Imamoto et al 1920; 
Mehta et al 2003). The metabolic effects of pioglitazone in 
improving insulin sensitivity, reducing blood glucose, LDL, 
triglyceride and certain inﬂ  ammatory mediators such as 
C-reactive protein levels further modulates the substrate for 
plaque formation and halts atheroma progression (Berhanu 
et al 2006; Szapary et al 2006). Metformin has also been 
noted to effectively reduce oxidative stress through inhibi-
tion of the PKC and NADPH oxidase pathways (Ouslimani 
et al 2005; Mahrouf et al 2006). While reducing the oxidative 
stress burden, metformin can ultimately improve endothelial 
function (De et al 2005). Metformin has also been shown to 
exert antiproliferative effects on vascular smooth muscle cells 
through inhibition of PKC pathway which can also slow the 
pace of plaque formation (Li et al 2005). Several human stud-
ies have indeed indicated that macrovascular complications of 
diabetes are reduced by metformin (Johnson et al 2005). Given 
the evidence, it appears that thiazolidinediones and metformin 
modulate endothelial function and plaque formation through 
distinctly separate pathways rendering their combination an 
attractive agent in decelerating diabetic atherosclerosis.
Diabetic cardiomypcarthy
and cardiac lipotoxicity
Approximately 34 years ago, Rubler and colleagues reported 
a series of four diabetic patients with congestive heart failure, Vascular Health and Risk Management 2007:3(6) 971
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normal epicardial coronary arteries and no other known 
causes of congestive heart failure in association with dia-
betic glomerulosclerosis (Rubler et al 1972). This new entity 
termed diabetic cardiomyopathy is frequently associated with 
diastolic dysfunction, left ventricular hypertrophy and ﬁ  brosis 
(Di Bonito et al 1996). Subsequent attempts in elucidating 
the putative mechanisms in animal models indicated a direct 
correlation between myocardial fat content and systolic and 
diastolic dysfunction. In a transgenic mice model which over 
expressed long chain Acyl-CO A synthase (ACS), Chiu and 
Schaffer were able to demonstrate dilated cardiomyopathy by 
sequential echocardiography along with excessive triglyceride 
accumulation in cardiomyocytes by both light and electron 
microscopy (Chiu et al 2001). In addition, incubation of 
cardiomyocytes with long-chain fatty acids resulted in DNA 
fragmentation and cardiomyocyte apoptosis (Kong and Rabkin 
2000). The obese (fa/fa) rat which develops diabetes with aging
is the closest animal model to human metabolic syndrome. 
A recent study by Zhao and colleagues demonstrated that the 
obese (fa/fa) rats will accumulate signiﬁ  cantly higher amounts 
of cardiac triglycerides as early as 7 weeks of age as compared 
to the normal lean rats. Further evaluation of myocardial per-
formance by echocardiography at 20 weeks of age revealed 
a dilated cardiomypoathy along with systolic and diastolic 
dysfunction in the obese (fa/fa) rats while the lean rats main-
tained the normal cardiac function at 20 weeks in this study 
(Zhou et al 2000). Despite these well-described animal models 
of myocardial lipotoxicity, the prevalence and mechanisms of 
cardiac lipotoxicity in humans remain unknown.
Effects of thiazolidinediones 
and metformin on diabetic 
cardiomyopathy
Animal studies indicate that pioglitazone can prevent diastolic 
dysfunction in advanced diabetes by improving myocardial 
fatty acid metabolism (Kim et al 2003). While these studies 
supported the cardiac lipotoxicity hypothesis and pointed to an 
emerging potential therapy, early use of thiazolidinediones in 
humans was associated with several reports of ﬂ  uid retention 
and exacerbation of congestive heart failure (CHF) (Kermani 
and Garg 2003; Cheng and Fantus 2004). A large multicenter 
clinical trial on 16,000 individuals with CHF aimed to assess 
potential beneﬁ  ts of pioglitazone in preventing complications 
of diabetes yielded mixed results; indicating that the favor-
able effects of pioglitaozne in reducing mortality are offset 
by increased number of hospital admissions for CHF exac-
erbations (Dormandy et al 2005). Therefore, further clinical 
studies are needed to elucidate the role of Thiazolidinediones 
in diabetic cardiomyopathy. Similarly, the initial concerns that 
metformin can cause lactic acidosis in patients with diabetes 
and congestive heart failure were revisited in a large retro-
spective study of over 12,000 patients (Eurich et al 2005). 
This study indicated that metformin alone or in combination 
therapy is associated with lower morbidity and mortality in 
patients with heart failure and type 2 diabetes as compared 
to sulfonylureas (Eurich et al 2005).
Summary and future directions
The increasing incidence of diabetes has paralleled the epidemic 
of obesity and insulin resistance. The exact mechanism(s) 
linking obesity to insulin resistance and diabetes remain 
to be explored but the evidence points to the three axes of 
oxidative stress, lipotoxicity and ER stress. Given the multiple 
putative pathways involved in the pathogenesis of diabetes 
and its complications, the treatment of this condition calls 
for simultaneous disruption of such pathologic phenomena. 
Therefore, it is anticipated that combination therapy with two 
or more agents will surpass the currently accepted indication 
of achieving optimal glucose control and expand to include 
most patients with diabetes. Pioglitazone and metformin are 
two insulin sensitizers with different mechanisms of action and 
distinctly separate effects on oxidative stress and lipotoxicity 
rendering their combination a potentially powerful tool in treat-
ing diabetes. In addition, the favorable effects of pioglitazone 
on endothelial function and cell surface receptor expression 
are in synergy with some of the anti-atherosclerotic effects of 
metformin; thus rendering combination therapy an attractive 
tool against accelerated atherosclerosis of diabetes.
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